

# Effect of Chinese herbal medicine Goreisan (Wulingsan) on vomiting with acute watery diarrhoea in children

**Submission date**  
05/04/2009

**Recruitment status**  
No longer recruiting

☐ Prospectively registered

☐ Protocol

**Registration date**  
20/04/2009

**Overall study status**  
Completed

☐ Statistical analysis plan

☐ Results

**Last Edited**  
20/04/2009

**Condition category**  
Infections and Infestations

☐ Individual participant data

☐ Record updated in last year

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr Selim Ahmed

### Contact details

Assistant Professor of Paediatrics  
The Institute of Child and Mother Health (ICMH)  
Matuail  
Dhaka  
Bangladesh  
1362  
+880 (0)2 754 2814  
drselim@gmail.com

## Additional identifiers

### Protocol serial number

N/A

## Study information

Scientific Title

Effect of Chinese herbal medicine Goreisan (Wulingsan) on vomiting with acute watery diarrhoea in children: a randomised, double-blind, placebo-controlled clinical trial

### **Study objectives**

Goreisan is effective in reducing the frequency of acute diarrhoea and associated vomiting in children.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Ethical Review Board of Institute of Child and Mother Health (ERB-ICMH) approved on the 1st April 2008

### **Study design**

Prospective randomised, double-blind, placebo-controlled clinical trial

### **Primary study design**

Interventional

### **Study type(s)**

Treatment

### **Health condition(s) or problem(s) studied**

Acute gastroenteritis with vomiting and diarrhoea

### **Interventions**

Subjects will be stratified by sex and randomised to Goreisan (Wulingsan) powder or placebo orally in a dose of 0.25 g/kg/day (maximum of 6.0 g/day) twice a day for 3 days.

Contact details for joint Principal Investigator:

Dr Ryuichi Uchida

Thailand-Japan Research Collaboration Center on Emerging and Re-emerging Infections (RCC-ERI)

6th Fl., Building 10

Department of Medical Sciences

Ministry of Public Health

Tiwanon Road

Muang, Nonthaburi 11000

Thailand

Tel: +66 (0)2 965 9748

Fax: +66 (0)2 965 9749

E-mail: ryuryu1\_u@yahoo.co.jp

### **Intervention Type**

Drug

### **Phase**

Phase IV

### **Drug/device/biological/vaccine name(s)**

Goreisan (Wulingsan)

**Primary outcome(s)**

1. Time to stopping of vomiting and diarrhoea after giving medicine or placebo during 72 hours of observation
2. Frequency of vomiting and diarrhoea after giving medicine or placebo during 72 hours of observation

**Key secondary outcome(s)**

1. Recovery from dehydration measured by WHO classification of dehydration in children with diarrhoea
2. Amount of oral rehydration sachets (ORS) and intravenous fluid used after giving medicine or placebo during 72 hours of observation

**Completion date**

14/05/2009

## **Eligibility**

**Key inclusion criteria**

1. Aged six months up to five completed years, either sex
2. Within 3 days onset of vomiting and watery diarrhoea before enrolment
3. Cases of diarrhoea fulfilling World Health Organization (WHO) criteria (loose motion 3 times and over within 24 hours)
4. Patients with diarrhoea who are still vomiting or have at least one episode of spontaneous vomiting within 3 hours before enrolment

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Child

**Lower age limit**

6 months

**Upper age limit**

5 years

**Sex**

All

**Key exclusion criteria**

1. Severe dehydration (WHO 2003) needing immediate intravenous fluid
2. Bloody diarrhoea
3. Anti-emetics used during this illness
4. Patients with diarrhoea and severe malnutrition

5. Any signs suggesting bacterial infections that need immediate antibiotic therapy
6. Any signs suggesting meningitis
7. Any signs suggesting ileus and/or intussusception
8. Any signs of serious systemic illness
9. Underlying congenital gastrointestinal disease
10. Other severe underlying diseases (i.e., cancer, acquired immune deficiency syndrome [AIDS], other immuno-compromised patients)
11. Past history of hospitalisation due to severe anaphylaxis to any kinds of foods or liquids

**Date of first enrolment**

14/05/2008

**Date of final enrolment**

14/05/2009

## Locations

**Countries of recruitment**

Bangladesh

**Study participating centre**

Assistant Professor of Paediatrics

Dhaka

Bangladesh

1362

## Sponsor information

**Organisation**

The Institute of Child and Mother Health (ICMH) (Bangladesh)

**ROR**

<https://ror.org/05dm6kv37>

## Funder(s)

**Funder type**

Industry

**Funder Name**

Kotaro Pharmaceutical Co., Ltd (Japan)

# Results and Publications

## Individual participant data (IPD) sharing plan

IPD sharing plan summary  
Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes